---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-069210"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:56:43.484500+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics raises $25M via pre-funded warrant private placement for SMARCA2 pipeline

## Summary
- Gross proceeds ~$25M from sale of 7,936,759 pre-funded warrants at $3.1499 each, exercise price $0.0001.
- Net proceeds estimated at $24.9M after offering expenses.
- Funds primarily support SMARCA2 portfolio: IV molecule PRT3789 clinical development and oral program IND.
- Cash runway now expected into 2026; closing expected Dec 13, 2023.
- Warrants are immediately exercisable, subject to 4.99% beneficial ownership cap (waivable to 19.99%).

## SEC filing metadata
- accession: 0000950170-23-069210
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017023069210/0000950170-23-069210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017023069210/prld-20231211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-069210
- JSON: https://secwatch.observer/filing/0000950170-23-069210.json
- Plain text: https://secwatch.observer/filing/0000950170-23-069210.txt

## Key facts
- Material Agreements
  Prelude Therapeutics Inc entered into Amended and Restated Registration Rights Agreement with the Company and the Purchasers (effective 2023-12-11).
  - Action: entry
  - Counterparty: the Company and the Purchasers
  - Effective: 2023-12-11
  source text: the Company and the Purchasers also entered into an Amended and Restated Registration Rights Agreement, dated as of December 11, 2023 (the “ Amended and Restated Registration Rights Agreement ”), providing for the registration for resale of the shares of Common Stock underlying the Pre-Funded Warrants
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017023069210/0000950170-23-069210-index.htm
- Material Agreements
  Prelude Therapeutics Inc entered into Securities Purchase Agreement with certain institutional accredited investors (effective 2023-12-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors
  - Effective: 2023-12-11
  source text: On December 11, 2023, Prelude Therapeutics Incorporated, a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to 7,936,759 shares of the Company’s voting common stock, par value $0.0001 per share (the “ Common Stock ”), at a price of $3.1499 per warrant with an exercise price of $0.0001 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017023069210/0000950170-23-069210-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.